ArticleJournal of gynecologic oncology2026
Direct comparison of 5-aminolevulinic acid photodynamic diagnosis and white light inspection for detecting peritoneal dissemination in advanced ovarian cancer: a pilot study.
Article in Journal of gynecologic oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveProtoporphyrin IX, a metabolite of 5-aminolevulinic acid (5-ALA), emits red fluorescence. Photodynamic diagnosis (PDD) using 5-ALA has been successfully applied in fluorescence-guided surgery for various malignancies. This pilot study directly compared the diagnostic performance of conventional white light (WL) inspection and 5-ALA-based PDD for detecting intraperitoneal dissemination in advanced ovarian cancer (OC).
methodsThis prospective single-center study included patients with advanced OC undergoing staging laparoscopy. Each patient received oral 5-ALA (20 mg/kg) 4 hours preoperatively. Tumor and non-tumor locations were identified under WL and fluorescent light (FL). Biopsy specimens were collected from tumor locations visible under both WL and FL, only under WL, and only under FL and from non-tumor locations visible under both WL and FL. Pathological examination confirmed malignancy, and results were correlated with imaging findings.
resultsSeven patients were enrolled between January and March 2019 and 71 biopsies were performed. The diagnoses included four cases of high-grade serous carcinoma, one clear cell carcinoma, one grade 3 endometrioid carcinoma, and one pseudomyxoma peritonei. The sensitivity, specificity, positive predictive value, and negative predictive value for detecting malignancy under WL were 87.8%, 59.0%, 82.7%, and 68.4%, respectively, compared with 96.0%, 90.5%, 96.0%, and 90.5% under FL. Additional metastatic lesions were identified in three patients subjected to 5-ALA imaging. No severe 5-ALA-related adverse events were observed.
conclusion5-ALA-based PDD demonstrated higher diagnostic accuracy than WL for detecting intraperitoneal dissemination of advanced OC. Its ability to enhance tumor detection may improve surgical precision and outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.